Side Effects After Direct-acting Antiviral Treatment

Completed

• Conditions: Chronic Hepatitis c

• Registration Number: NCT03346941
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

The objective of this study was to assess the incidence of side effects after direct-acting antiviral therapy in patients with chronic hepatitis C virus infection.

Detailed Description

Direct-acting antiviral (DAA)-based treatments are today very effective The objective of this study was to assess the incidence of side effects after DAA therapy in patients with chronic hepatitis C virus infection.

Study Timeline

• Study Start: 2016-05-01
• Primary Completion: 2017-09-30
• Study Completion: 2017-10-31
• Status Verified: 2017-11
• Study First Submitted: 2017-11-15
• Study First Submitted QC: 2017-11-15
• Last Update Submitted: 2017-11-15
• Study First Posted: 2017-11-20
• Last Update Posted: 2017-11-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 95

Inclusion Criteria

• 18 years of age or older
• Hepatitis C virus infection
• Treatment by direct-acting antiviral combination

Read More

Exclusion Criteria

• HIV coinfection

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of side effects	Within treatment duration, i.e. 8, 12 or 24 weeks after treatment initiation	Incidence of side effects occurring during treatment duration. Treatment duration may be of 8 weeks, 12 weeks or 24 weeks depending on treatment combination.

Trial Locations

Locations (1)

Croix-Rousse Hospital, Hospices Civils de Lyon; 🇫🇷 Lyon, France